carreño project leader life cycle management & drug ... · pdf filecarreño...
TRANSCRIPT
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Dr.
Beg
oña
Car
reño
Proj
ect L
eade
r Life
Cyc
le M
anag
emen
t &
Dru
g D
eliv
ery
Tech
nolo
gies
Nov
artis
Pha
rma,
Bas
el, C
H
Rec
ent a
dvan
ces
in d
rug
deliv
ery
and
how
th
ey a
ffect
Life
Cyc
le M
anag
emen
t in
Ph
arm
aceu
tical
Indu
stry
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Age
nda
•B
rief i
ntro
duct
ion
to N
ovar
tis•
Pha
rmac
eutic
al in
dust
ry tr
ends
•Li
fe C
ycle
Man
agem
ent (
LCM
) and
Dru
g D
eliv
ery
Tech
nolo
gies
(D
DT)
: –
Def
initi
on–
LCM
& D
DT
at N
ovar
tis–
LCM
&D
DT:
wha
t do
drug
del
iver
y sy
stem
s of
fer?
Exa
mpl
es–
Sol
ubili
satio
n th
roug
h na
noni
satio
n: E
xam
ples
–By
pass
ing
Firs
t pas
s liv
er e
ffect
: Exa
mpl
es–
Con
veni
ance
and
com
plia
nce:
Exa
mpl
es–
Pat
ient
con
veni
ance
and
com
plia
nce
expr
esse
d in
sal
es•
Con
clus
ions
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nov
artis
Org
anis
atio
n
•Car
diov
ascu
lar &
Met
abol
ism
•Onc
olog
y &
Hem
atol
ogy
•Neu
rosc
ienc
e•R
espi
rato
ry &
Der
mat
olog
y•I
nfec
tious
Dis
ease
s,
Tran
spla
ntat
ion
& Im
mun
olog
y (ID
TI)
•Oph
thal
mic
s•A
rthr
itis/
Bone
/Gas
troi
ntes
tinal
/U
rolo
gy (A
BGU
)N
OVA
D
•Gen
eric
s
•For
mer
Chi
ron
•Nov
el/c
onve
ntio
nal v
acci
nes
•Blo
od te
stin
g
Cons
umer
Hea
lth•O
TC•A
nim
al H
ealth
•Med
ical
Nut
ritio
n•G
erbe
r•C
IBA
Visi
onSand
ozPh
arm
aceu
tical
s
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nov
artis
achi
evem
ents
–8
sign
ifica
nt a
ppro
vals
in 2
005,
incl
udin
g 2
high
prio
rity
revi
ews
–73
pro
ject
s in
dev
elop
men
t
–4
new
com
poun
ds to
be
filed
in 2
006
for a
ppro
val
–R
anke
d as
one
of t
he fa
stes
t and
mos
t pro
duct
ive
in
deve
lopm
ent
–Le
adin
g Pa
rtne
r of t
he F
DA
in C
ritic
al P
ath
Initi
ativ
e
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Indu
stry
Tre
nds
: R&
D P
rodu
ctiv
ity is
Dec
linin
g
Glo
bal P
harm
aR
&D
exp
endi
ture
s (in
$ b
n)#
NM
Esap
prov
ed b
y FD
A
Sour
ce:
FDA
CD
ER
& C
BE
R; E
valu
ate
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Safe
ty re
late
d w
ithdr
awal
s of
ora
l pro
duct
s in
the
US:
Num
ber o
fpa
tient
s ex
pose
d in
the
12 m
onth
s pr
ior t
o w
ithdr
awal
(‘00
0s)
Sour
ce:
IMS
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
The
cost
to d
evel
op a
dru
g pr
oduc
t asc
ends
to $
900
Man
d 10
-15
year
s be
fore
laun
ch
Poss
ible
Sol
utio
ns
Res
earc
hD
evel
opm
ent
-A
ccel
erat
e de
velo
pmen
t tim
elin
es-
Lias
e w
ith re
gula
tory
aut
horit
ies
over
dev
elop
men
t pat
hs
-Life
Cyc
le M
anag
emen
t
Prot
eono
mic
sG
enom
ics
etc
Lice
nse-
in
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Life
-Cyc
le M
anag
emen
t (LC
M)
Obv
ious
in s
ome
indu
strie
s....
.
Wha
t doe
s it
mea
n in
Nov
artis
?
All
mea
sure
s/ p
roje
cts
initi
ated
-i
n ad
ditio
n to
mai
nstre
am d
evel
opm
ent –
that
are
inte
nded
to e
nhan
ce th
e va
lue
of a
bra
ndth
roug
hout
its
life
cycl
e to
the
bene
fit o
f the
pat
ient
s an
d N
ovar
tis.
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nov
artis
LC
M&
DD
T or
gani
satio
n
11 p
harm
acis
ts /c
hem
ists
with
At l
east
sev
eral
yea
rs o
f exp
erie
nce
in
drug
pro
duct
dev
elop
men
t
appl
icat
ion
of D
DT
to p
roje
cts
LCM
str
ateg
ies
Indi
vidu
al a
reas
of e
xper
tise
(ora
l/
pare
nter
al/tr
ansm
ucos
al)
Expe
rienc
e in
pat
ent s
trat
egie
s an
d
pate
nt li
fe e
xten
sion
s
Expe
rts
in c
ompe
titiv
e en
viro
nmen
t
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Eas
t Han
over
Orle
ans
Tsuk
uba
Bas
el
Mum
bai Si
ngap
ore
Trul
y G
loba
l Pha
rmac
eutic
al &
Ana
lytic
al D
evel
opm
ent
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nov
artis
LC
M&
DD
T Ta
sks
Cont
ribut
ion
to
late
-pha
se L
CMIn
itiat
ion
of
proa
ctiv
e LC
M
Lead
feas
ibili
ty
stud
ies
both
inte
rnal
ly
and
with
ex
tern
al p
artn
ers
Info
rmat
ion
onco
mpe
titor
s
Asse
ssm
ent o
f ex
tern
alte
chno
logi
es
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–w
hy is
it s
o im
port
ant
?•
Mai
nstre
am d
evel
opm
ent f
ocus
es o
n br
ingi
ng th
erap
eutic
ben
efits
to
pat
ient
s as
rapi
dly
as p
ossi
ble
(Gliv
ec: d
evel
opm
ent <
100
0 da
ys)
•LC
M fo
cuse
s on
tailo
ring
drug
pro
duct
to p
atie
nt‘s
nee
ds a
nd
pref
eren
ces
and
on o
ptim
isin
g th
e th
erap
eutic
val
ueof
dru
g pr
oduc
ts
Idea
lly L
CM
lead
s to
a h
ighe
r mar
ket s
hare
for t
he b
rand
in
crea
sed
sale
s
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–ho
w is
it a
chie
ved
in g
ener
al ?
Thro
ugh…
…
•New
indi
catio
ns•A
ltern
ativ
e dr
ug d
eliv
ery
syst
ems,
pack
agin
g an
d de
vice
s•A
ltern
ativ
e dr
ug s
ubst
ance
pro
pert
ies
•Im
prov
ed m
anuf
actu
ring
proc
esse
s
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nov
artis
LC
M&
DD
T: T
he D
DT
Part
–Se
arch
for i
nnov
ativ
e D
rug
Del
iver
y Te
chno
logi
es
–A
sses
smen
t of e
xter
nal t
echn
olog
y»
Fit t
o N
ovar
tis d
evel
opm
ent p
ortfo
lio?
»Fi
t to
Nov
artis
tech
nolo
gypo
rtfo
lio?
–Ev
alua
tion
of (t
echn
ical
) fea
sibi
lity
»Pa
per a
sses
smen
t»
Feas
ibili
ty tr
ial u
p to
(and
incl
udin
g) c
linic
al tr
ial (
step
wis
eap
proa
ch, f
inal
pro
of o
f fea
sibi
lity)
–C
oord
inat
e ev
alua
tion
of e
xter
nal D
DT
allia
nce
prop
osal
s
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–w
hat d
o D
DTs
offe
r ?
Pat
ient
ben
efits
suc
h as
:
–Im
prov
emen
t of t
hera
peut
ic in
dex
(effi
cacy
/ saf
ety)
–Im
prov
emen
t of c
onve
nien
cefo
r pat
ient
–Im
prov
emen
t of p
atie
nt c
ompl
ianc
e
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–w
hat d
o D
DTs
offe
r ?
Impr
ovem
ent o
f effi
cacy
/ saf
ety
Red
uced
sid
e ef
fect
sIn
crea
sed
bioa
vaila
bilit
y &
redu
ced
varia
bilit
yO
ptim
ized
bas
ed o
n PK
-PD
cor
rela
tion
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–w
hat d
o D
DTs
offe
r ?
Impr
ovem
ent o
f pat
ient
con
veni
ence
•Red
uced
dos
ing
freq
uenc
y•R
educ
ed in
ject
ion
volu
me
•Pre
ferr
ed a
dmin
istr
atio
n ro
ute
•Im
prov
emen
t of s
wal
low
-abi
lity
•Com
bina
tion
prod
ucts
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–w
hat d
o D
DTs
offe
r ?
Impr
ovem
ent o
f pat
ient
com
plia
nce
•Adm
inis
trat
ion
with
out w
ater
•Opt
imal
dos
age
form
s fo
r pat
ient
pop
ulat
ions
(chi
ldre
n /
elde
rly)
•Opt
imiz
ed d
osag
e fo
rm fo
r dis
ease
(e.g
. acu
te tr
eatm
ent)
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
–th
e fir
st e
xam
ple
1898
2 ye
ars
afte
r the
foun
datio
n o
f Hof
fman
n-La
Roc
he
•A
coug
h sy
rup
cont
aini
ng R
oche
's T
hioc
ol
•Th
e sy
rup'
s or
ange
flav
ourm
akes
it a
suc
cess
The
3rd
laun
ched
pro
duct
is a
LC
M p
rodu
ct:
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
List
of s
ome
of th
e D
DTs
that
add
ress
diff
eren
t iss
ues
Solu
bilit
y/pe
rmea
bilit
yN
ano/
mic
roni
satio
nC
yclo
dext
rins
Hot
mel
t ext
rusi
onLi
pid
form
ulat
ions
1st p
ass
met
abol
ism
Tran
smuc
osal
deliv
ery,
e.g.
buc
cal,
nasa
l del
iver
ytr
ansd
erm
al, p
aren
tera
lde
liver
y
Con
trol
led
rele
ase
(sus
tain
ed)
Mat
rix ta
blet
s, c
oate
dm
ultip
artic
ulat
eO
smot
icsy
stem
s, G
astr
ic re
tent
ion
syst
ems,
dep
ofo
rmul
atio
ns
Patie
nt c
onve
nien
ce/c
ompl
ianc
eO
DT,
thin
film
s, p
atch
es e
tcA
ltern
ativ
e de
liver
y ro
ute
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
& D
DT
exam
ples
on
how
to a
ddre
ss s
olub
ility
pro
blem
s
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Solu
bilit
y pr
oble
ms
•40%
of t
he s
elec
ted
drug
mol
ecul
es fo
r dev
elop
men
t are
lipo
phili
c
•Fro
m th
e N
CEs
app
rove
d in
200
2, >
50
% w
ere
poor
lyso
lubl
e in
w
ater
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nan
osis
ing
: Why
do
we
need
nan
opar
ticle
s in
dru
g de
liver
y ?
200
nmpr
otec
tive
stab
ilize
r
40 µ
m
To d
ecre
ase
the
part
icle
siz
e an
din
crea
se d
rug
part
icle
su
rfac
e ar
ea, w
hich
lead
s to
: Par
ente
ral r
oute
:
•i.v
. inj
ecta
bilit
y of
nan
osus
pens
ions
w
ithou
t ris
k of
thro
mbo
sis
•S
olub
iliza
tion
of p
oorly
sol
uble
drug
s w
ithou
t a ri
sk o
f pre
cipi
tatio
n
•E
ntra
pmen
t of i
rrita
ting
drug
s
prev
entio
n of
phl
ebiti
s at
inje
ctio
n si
te
Ora
l rou
te:
•E
nhan
ced
in-v
ivo
diss
olut
ion
•E
nhan
ced
abso
rptio
n
•R
educ
ed v
aria
bilit
y
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Com
mer
cial
ly a
vaila
ble
“nan
o-sc
ale”
ther
apeu
tics
•Li
poso
mes
(Dox
il, D
auno
Xom
e,M
ycoc
et, A
mB
iom
e, V
isud
yne)
•Al
bum
in-b
ound
nan
opar
ticle
s(A
brax
ane,
AP
P
•G
adol
iniu
m c
hela
tefo
r MR
I im
agin
g (M
agne
vist
, Gd-
DTP
A D
imeg
lum
ine,
B
erle
x)
•Iro
n ox
ide
parti
cles
for M
RI i
mag
ing
(Fer
idex
, Ber
lex)
•M
icro
emul
sion
s(N
eora
l®C
yclo
spor
ine,
Nov
artis
)
•P
rodu
cts
usin
g É
lan’
s N
anoC
ryst
alte
chno
logy
(Rap
amun
e®,W
yeth
, E
men
d®, M
erck
)
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nov
artis
Impr
oved
Bio
avai
labi
lity
and
redu
ced
Varia
bilit
y th
roug
h N
eora
l mic
roem
ulsi
on fo
rmul
atio
n 0
200
400
600
800
1000
1200
1400
1600
0.0
2.0
4.0
6.0
8.0
Tim
e (h
)
Concentration (ng/ml)
0
200
400
600
800
1000
1200
1400
1600
02
46
8Ti
me
(h)
Concentration (ng/ml)
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Mic
ro/n
anon
isat
ion
alte
rnat
ives
: > 1
0 D
Dco
mpa
nies
Top-
dow
n te
chno
logi
es:
•N
ano-
Mill
ing
•H
omog
eniz
atio
n
Bot
tom
-Up
tech
nolo
gies
:
•P
reci
pita
tion
•S
CF
combinatio
ns
Ela
nB
axte
r
Sky
epha
rma
Pha
rmas
ol
Bax
ter
Sol
iqs
Dow
Sol
uBes
t
Nek
tar
Eiff
el
Ferr
oA
ctiv
ery
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
How
do
the
nano
sizi
ngte
chno
logi
es d
iffer
?
•Te
chno
logy
prin
cipl
e (b
otto
m u
p vs
. top
dow
n)
•Es
tabl
ishe
d sc
ale
and
mat
urity
(GM
P, d
ev. s
tage
)
•C
reat
ion
of a
mor
phou
s or
cry
stal
line
nano
part
icle
s
•C
hoic
e of
sta
biliz
ers:
pol
ymer
s an
d/or
sur
fact
ants
•C
oatin
g ef
ficie
ncy
•U
se o
r om
ittan
ce o
f a s
olve
nt
•IP
pro
tect
ion
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nan
onis
atio
n: N
anoC
ryst
alte
ch. i
n 4
mar
kete
d dr
ugs
•Wye
th’s
imm
unos
uppr
essa
ntR
apam
une®
(siro
limus
)
•For
mul
ated
in a
tabl
et
•Pre
viou
sly
avai
labl
e on
ly a
s an
ora
l sol
utio
n in
bot
tles
or s
ache
ts w
hich
re
quire
d: Ref
riger
atio
n st
orag
eM
ust b
e m
ixed
with
wat
er o
r ora
nge
juic
e pr
ior t
o ad
min
istra
tion
•Mer
ck’s
Em
end®
(Apr
epita
nt) f
orm
ulat
ed in
a c
apsu
le
Con
veni
ance
&
Com
plia
nce
Bio
avai
labi
lity
impr
ovem
ent
Em
end
was
dev
elop
ed a
s an
NC
E
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nan
onis
atio
n: N
anoC
ryst
alte
chno
logy
in 4
mar
kete
d dr
ug p
rodu
cts
(Con
t)
•Abb
ott‘
s Tr
iCor
®(fe
nofib
rate
)
•For
mul
ated
in a
tabl
et•C
an b
e ad
min
iste
red
with
or w
ithou
t foo
dIn
the
orig
inal
form
ulat
ion
adm
inis
tratio
n w
itha
mea
l was
nee
ded
•Meg
ace®
ES
(meg
estro
l)fo
rmul
ated
as
oral
sol
utio
n
•Im
prov
ed d
isso
lutio
n ra
te a
nd b
ioav
aila
bilit
y P
atie
nts
are
able
to ta
ke o
ne-fo
urth
of t
he v
olum
e of
the
orig
inal
pro
duct
Con
veni
ance
&
Com
plia
nce
Bio
avai
labi
lity
impr
ovem
ent
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nan
onis
atio
n-Sk
yeph
arm
a: ID
D-P
: one
mar
kete
d pr
oduc
t
Firs
t Hor
izon
Trig
lide™
(Fen
ofib
rate
):
•For
mul
ated
in a
tabl
et
•Can
be
adm
inis
tere
d w
ith o
r with
out f
ood
In th
e or
igin
al fo
rmul
atio
n ad
min
istra
tion
with
a
mea
l was
nee
ded
Con
veni
ance
&
Com
plia
nce
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Nan
otec
hnol
ogy
Dev
elop
men
t: a
few
con
clud
ing
rem
arks
•Th
e na
no-b
ased
bio
med
ical
tech
nolo
gy c
andi
date
s ar
e ex
pand
ing*
•68
% in
crea
se in
the
clin
ical
pip
elin
e fr
om 2
005
•13
0 na
note
ch-b
ased
dru
gs a
nd d
eliv
ery
syst
ems
•12
5 de
vice
s or
dia
gnos
tic te
sts
•D
eman
d fo
r nan
otec
hnol
ogy
heal
th c
are
prod
ucts
in th
e U
S is
pro
ject
ed to
incr
ease
nea
rly 5
0 pe
rcen
t per
yea
r to
$6.5
bill
ion
in 2
009.
* So
urce
: 200
6 N
anom
edic
ine,
Dev
ice
& Di
agno
stic
Rep
ort,
Nat
iona
l Hea
lth In
form
atio
n, L
LC.
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
& D
DT
exam
ples
on
how
to a
ddre
ss 1
st p
ass
met
abol
ism
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Exam
ple
of a
Dos
age
Form
with
Incr
ease
d B
ioav
aila
bilit
y an
d R
educ
ed F
irst-P
ass
Met
abol
ism
024681012
02
46
810
12T
ime
(h)
Plasma concentration (ng/ml)
Zydi
s 10
mg
Eld
epry
l 10m
gZy
dis
1.25
mg
10 m
g Zy
dis
tabl
et d
eliv
ers
near
ly e
ight
tim
esth
e co
ncen
trat
ion
of s
eleg
iline
than
an
ord
inar
y 10
mg
tabl
et
Sour
ce:
http
://w
ww
.car
dina
l.com
/pts
/con
tent
/abo
utus
/who
wea
re/b
roch
/CH
-PTS
-DLV
-Zyd
is.p
df
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
LCM
& D
DT-
Exam
ples
of p
atie
nt c
onve
nien
ce
and
com
plia
nce
impr
ovem
ent
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Exam
ple
of In
hala
tion
repl
acin
g In
ject
able
dosa
ge fo
rm
Exub
era:
Pul
mon
ary
INSU
LIN
App
rove
d by
the
FDA
in J
anua
ry 2
006
1st n
ew a
dmin
istr
atio
n ro
ute
sinc
e it
was
dis
cove
red
in 1
921!
!
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Exam
ple
of In
hala
tion
repl
acin
g In
ject
able
dosa
ge fo
rmH
epat
ic s
inus
oida
l pla
sma
insu
lin le
vels
for E
xube
rain
hala
tion
and
Hum
ulin
IVC
-infu
sed
insu
linH
epat
ic g
luco
se lo
ad fo
r Exu
bera
inha
latio
n an
d H
umul
inIV
C-in
fuse
d in
sulin
Lung
s pr
ovid
e an
attr
activ
e ta
rget
for b
oth
syst
emic
and
loca
l dru
g de
liver
ySo
urce
: ht
tp://
diab
etes
.dia
bete
sjou
rnal
s.or
g/cg
i/con
tent
/full/
54/4
/116
4
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Exam
ple
of O
ral r
epla
cing
Inje
ctab
ledo
sage
form
012345678
030
6090
120
150
180
210
240
270
300
Brita
ject
(2.5
mg
sc)
Zydi
s Fo
rmul
atio
n A
Zydi
s Fo
rmul
atio
n B
Caps
ule
form
ulat
ion
Zydi
sap
omor
phin
eta
blet
del
iver
s co
mpa
rabl
e bi
oava
ilabi
lity
to in
ject
able
apom
orph
ine
Sour
ce:
http
://w
ww
.car
dina
l.com
/pts
/con
tent
/abo
utus
/who
wea
re/b
roch
/CH
-PTS
-DLV
-Zyd
is.p
df
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Exam
ple
of c
onve
nien
ce a
nd c
ompl
ianc
e im
prov
emen
t
Zolm
itrip
tan
–a
mig
rain
e dr
ug
Fast
mel
t tab
lets
:
Can
be
take
n w
ithou
t wat
eran
y tim
e an
d an
ywhe
re,
even
whe
n pa
tient
feel
s na
useo
us
Nas
al s
pray
:
Shor
ter t
max
Earli
er s
ympt
om re
lief
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Patie
nt c
onve
nian
ce a
nd c
ompl
ianc
e ex
pres
sed
in s
ales
Sour
ce: S
. Milo
jevi
c, D
rug
deliv
ery
Part
ners
hip
Con
fere
nce,
Eur
ope,
200
4
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Life
-Cyc
le M
anag
emen
t –va
lue
of p
aten
t pro
tect
ion
It’s
com
mer
cial
rew
ard
for i
nnov
atio
n!
time
Inno
vatio
nPa
tent
(R
&D
)fil
ing
Laun
chB
asic
Pate
ntEx
piry
LCM
Pate
ntFi
ling
(„2n
d in
nova
tion“
,se
cond
ary
pate
nts)
Seco
ndar
yPa
tent
Expi
ry
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Con
clus
ions
LCM
thro
ugh
tech
nica
l lin
e ex
tens
ions
pro
vide
s th
e fo
llow
ing
bene
fits:
»Im
prov
emen
t of t
hera
peut
ic v
alue
of d
rug
prod
ucts
thro
ugh
impr
oved
ther
apeu
tic in
dex
(effi
cacy
/ saf
ety)
»Im
prov
emen
t of c
onve
nien
cefo
r pat
ient
»Im
prov
emen
t of p
atie
nt c
ompl
ianc
e
»E
nric
hes
Nov
artis
por
tfolio
»In
crea
ses
the
busi
ness
val
ue o
f a b
rand
»P
rolo
ngs
the
life
cycl
e of
a b
rand
Glo
bal T
echn
ical
Res
earc
h &
Deve
lopm
ent
Ack
now
ledg
emen
ts
•La
Soc
ieda
d E
spañ
ola
de Q
uím
ica
Tera
péut
ica
•N
ovar
tis P
harm
a, s
peci
ally
to:
–C
hris
tine
Boh
man
n an
d Jo
erg
Ogo
rka
for r
evie
win
g th
ese
slid
es–
Bar
bara
Lue
ckel
, Nic
olet
ta L
oggi
a, M
icha
el A
mbu
ehl a
nd
Joer
n-S
tefa
n Lu
cks
for l
endi
ng m
e so
me
of th
eir s
lides
.....
and
of c
ours
e to
all
of y
ou fo
r you
r tim
e to
day!
Con
tact
det
ails
: beg
ona.
carr
eno-
gom
ez@
nova
rtis
.com